Eric Drolshagen, MD
Family Medicine · Fort Smith, ARNPI 1598285181
Payments from drug & device makers
Across 426 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$633
- Lilly USA, LLC$573
- Amgen$527
- Pfizer$468
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 111 | $1,706 |
| AstraZeneca | 50 | $1,502 |
| Novo Nordisk | 36 | $633 |
| Lilly USA, LLC | 46 | $573 |
| Amgen | 30 | $527 |
| Pfizer | 41 | $468 |
| Bayer | 9 | $373 |
| GSK | 13 | $302 |
| Otsuka America Pharmaceutical, Inc. | 11 | $242 |
| Esperion Therapeutics, Inc. | 3 | $218 |
| Johnson & Johnson | 10 | $199 |
| Sanofi-aventis U.S. LLC | 5 | $169 |
| Eisai Inc. | 4 | $147 |
| Abiomed | 1 | $133 |
| Stryker | 1 | $121 |
| Dexcom, Inc. | 6 | $118 |
| Exact Sciences | 7 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $98 |
| Phathom Pharmaceuticals, Inc. | 5 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $91 |
| Astellas Pharma US Inc | 4 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Merck | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Boehringer Ingelheim | 3 | $51 |
| Mylan Specialty L.p. | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Medtronic | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$625
- BREZTRI$588
- FARXIGA$468
- AIRSUPRA$338
- Kerendia$250
- Impella$133
- EVENITY$126
- SOLIQUA 100/33$125
- NEXLIZET$123
- NEXLETOL$123
- Dayvigo$123
- TRELEGY ELLIPTA$123
- FlowTriever$121
How this compares
$8,348 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 179 | $189,473 |
| OzempicSemaglutide | 152 | $173,591 |
| JardianceEmpagliflozin | 166 | $157,531 |
| EliquisApixaban | 124 | $113,854 |
| FarxigaDapagliflozin Propanediol | 99 | $107,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $88,406 |
| XareltoRivaroxaban | 80 | $76,868 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $40,411 |
| TrulicityDulaglutide | 28 | $33,892 |
| MyrbetriqMirabegron | 26 | $28,307 |
| LinzessLinaclotide | 14 | $22,430 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,254 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $20,496 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $17,482 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $16,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $573 | $223,365207 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $633 | $191,072166 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $51 | $163,318178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,502 | $136,500153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $302 | $122,016180 claims |
| PfizerEliquis, Premarin | $468 | $120,124144 claims |
| Johnson & JohnsonXarelto | $199 | $76,86880 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $28,30726 claims |
| AbbVieLinzess | $1,706 | $22,43014 claims |
| MerckJanuvia | $64 | $11,99615 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $91 | $7,30113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Fort Smith
- Glenn GibbonsFort Smith$179K
- Thinh NguyenFort Smith$28K
- Allen BeachyFort Smith$21K
- Michael CallawayFort Smith$15K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.